SCHEMBL793482

SCHEMBL793482

NCCc1cc2cc(F)ccc2s1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 4/20 0.42
ASIC3 Q9UHC3 1/20 0.42
LOXL2 Q9Y4K0 1/20 0.42
IDO1 P14902 1/20 0.41
TAAR1 Q96RJ0 2/20 0.39
SLC6A2 P23975 1/20 0.39
SLC6A4 P31645 1/20 0.39
AKR1B1 P15121 1/20 0.38
AXL P30530 1/20 0.36
GFER P55789 1/20 0.36
HTR2A P28223 2/20 0.36
MPO P05164 1/20 0.36
TRPM8 Q7Z2W7 1/20 0.36
MAOB P27338 1/20 0.35
AGXT P21549 1/20 0.35
HTR1A P08908 1/20 0.35
KMT2A Q03164 1/20 0.35
TUBB4A P04350 1/20 0.35
TUBB P07437 1/20 0.35
TUBA3C P0DPH7 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL20337967 0.84 CYP2A6 (0.56) CYP2A6ASIC3LOXL2IDO1SLC6A2
SCHEMBL2091204 0.80 AKR1B1 (0.35) CYP2A6ASIC3LOXL2AKR1B1TUBB4A
SCHEMBL9116915 0.79 HSP90AA1 (0.45) CYP2A6ASIC3LOXL2TAAR1AKR1B1
SCHEMBL14756257 0.79 CYP2A6 (0.42) CYP2A6ASIC3LOXL2TAAR1AGXT
SCHEMBL10363761 0.78 AKR1B1 (0.39) CYP2A6ASIC3LOXL2SLC6A2SLC6A4
SCHEMBL2097026 0.78 CYP2A6 (0.40) CYP2A6ASIC3LOXL2SLC6A2SLC6A4
SCHEMBL793711 0.78 CYP2A6 (0.58) CYP2A6ASIC3LOXL2SLC6A2SLC6A4
SCHEMBL4889443 0.76 CYP2A6 (0.71) CYP2A6ASIC3LOXL2TAAR1AGXT
SCHEMBL24303551 0.75 BACE1 (0.53) CYP2A6SLC6A2SLC6A4AXLGFER
SCHEMBL15981445 0.73 CYP2A6 (0.38) CYP2A6ASIC3LOXL2TAAR1AGXT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8946260-B2 17α-hydroxylase/C17,20-lyase inhibitors NOVARTIS AG (CH) 2015-02-03 US disclosed
US-8946260-B2 17α-hydroxylase/C17,20-lyase inhibitors NOVARTIS AG (CH) 2015-02-03 US disclosed
US-8946260-B2 17α-hydroxylase/C17,20-lyase inhibitors NOVARTIS AG (CH) 2015-02-03 US disclosed
US-20140045872-A1 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS NOVARTIS AG (CH) 2014-02-13 US disclosed
US-20140045872-A1 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS NOVARTIS AG (CH) 2014-02-13 US disclosed
US-20140045872-A1 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS NOVARTIS AG (CH) 2014-02-13 US disclosed
EP-2627648-A1 17aHYDROXYLASE/C17,20-LYASE INHIBITORS Novartis AG (CH) 2013-08-21 EP disclosed
WO-2012035078-A1 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS NOVARTIS AG (CH) 2012-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140045872-A1 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS CYP17A1, CYP21A2, HSD17B1 CYP2A6 112/4885ASIC3 1579/4885LOXL2 3032/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.